ATB Therapeutics

# ATB Therapeutics: High-Level Overview

ATB Therapeutics is a biopharmaceutical company, not a technology company in the traditional sense—though it does develop proprietary technology platforms. The company develops next-generation antibody therapies for cancer and immune diseases using its ATBioFarm platform, which enables the production of "atbodies"—engineered antibodies that combine multiple targeting and killing domains within a single molecule.[1][2]

The company addresses a critical gap in the antibody-drug conjugate (ADC) market. Traditional ADCs face limitations in efficacy, stability, and safety profiles. ATB Therapeutics solves this by creating weaponized antibodies that incorporate novel cell-killing mechanisms—including enzymatic functionalities—directly within targeted antibodies, rather than relying on external conjugation methods.[2] This approach promises increased potency, stability, and targeted exposure compared to conventional approaches.[1] The company serves patients with hematological malignancies, solid tumors, and autoimmune diseases, with clinical trials targeted to begin in 2028.[3]

ATB Therapeutics has demonstrated strong early momentum, raising a €54 million Series A in November 2024 led by EQT Life Sciences.[2][3] The company is expanding its R&D operations to Ghent while establishing a cutting-edge pilot manufacturing facility in Marche-en-Famenne, Belgium.[2]

Origin Story

ATB Therapeutics was founded in 2018 in Marche-en-Famenne, Belgium, by co-founders Max and Bertrand, who met at university.[3] The founding story reflects a deliberate market-gap analysis: the founders identified both the promise and limitations of existing ADC therapies and recognized that an alternative production method could address critical unmet needs.[3]

The company's technological foundation draws from plant-based production methods originally developed by Belgian Professor Marc Van Montague in the 1980s.[3] Rather than being discouraged by the novelty of applying this approach to antibody engineering, the founders embraced what they describe as their "initial naïve mindset" and launched with optimism into a completely new approach.[3] This early belief has been validated by substantial investor support and recruitment of industry veterans, including Torsten Dreier (co-founder of argenx) as Chief Development Officer and Mark Throsby (former Chief Scientific Officer of Merus) as Executive Chair.[3]

Core Differentiators

• Proprietary ATBioFarm Platform: Enables scalable, single-step production of sophisticated biologics that combine multiple targeting and killing domains, addressing manufacturing challenges that plague traditional ADC approaches.[2]

• Novel Mechanism of Action: Atbodies incorporate enzymatic functionalities and cell-killing mechanisms directly within antibodies, rather than relying on external conjugation—enhancing both efficacy and safety.[2]

• Dual Pipeline Strategy: The company is developing both internal assets (including atbody-st-2 for solid tumors and atbody-hm-1 for hematologic neoplasms) while positioning the platform for partnerships with other biotech and pharmaceutical companies.[2][3]

• Experienced Leadership: The recruitment of proven executives from successful biotech companies signals both validation and operational maturity for a company founded just seven years ago.[3]

Role in the Broader Tech Landscape

ATB Therapeutics is riding the wave of next-generation biologics innovation in oncology and immunotherapy. The timing is particularly favorable: the ADC market has matured, revealing both its therapeutic potential and its limitations. Regulatory agencies and clinicians are increasingly receptive to novel mechanisms of action that address unmet clinical needs.[2]

The company's plant-based manufacturing approach represents a convergence of biotechnology and agricultural bioengineering—a trend gaining traction as companies seek sustainable, scalable alternatives to traditional cell-based production. By anchoring its operations in Belgium (where the original technology was developed), ATB Therapeutics is also strengthening Europe's position as a hub for deep-tech biopharmaceutical innovation, particularly in antibody engineering.

The platform's potential for partnering with larger pharmaceutical companies positions ATB as an enabling technology provider, not just a drug developer—a model that amplifies its influence across the broader oncology and immunology ecosystems.[3]

Quick Take & Future Outlook

ATB Therapeutics is at an inflection point. With €54 million in Series A funding, world-class leadership, and a differentiated platform, the company is well-positioned to achieve its 2028 clinical trial initiation target. The real test will be whether atbodies deliver the superior efficacy and safety profiles the founders envision—and whether the platform proves as versatile for partnerships as the company hopes.

The next 2-3 years will likely determine whether ATB becomes a standalone drug developer, a platform licensor to larger pharma, or both. Either path positions the company as a meaningful contributor to the next generation of cancer and autoimmune therapies. The convergence of proven leadership, differentiated technology, and substantial capital creates a rare opportunity in the crowded ADC space.